Status:

COMPLETED

Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU

Lead Sponsor:

University of Missouri-Columbia

Collaborating Sponsors:

BioMarin Pharmaceutical

Conditions:

Phenylketonurias

Eligibility:

All Genders

18-55 years

Brief Summary

The goal of the proposed study is to elucidate neurologic and neuropsychological improvements associated with Palynziq-related reduction in plasma Phe levels in individuals with PKU. To this end, inve...

Detailed Description

Past studies have documented PKU-related disruptions in brain phenylalanine (Phe) levels, white matter (WM) and gray matter (GM) brain structures, functional connectivity, and neurocognitive functioni...

Eligibility Criteria

Inclusion

  • Age 18-55 years
  • Participants identified by newborn screening with PKU as evidenced by a blood Phe level ≥ 360μmol/L; received treatment within the first 30 days of life
  • Previously received a neuropsychological and neuroimaging evaluation (as part of previously described MU or BCH studies) prior to enrollment in the present study (while Palynziq-naïve).
  • Capable of providing informed consent
  • Presently being treated with Palynziq and has demonstrated a prolonged Phe response to Palynziq (as reflected by at least 3 consecutive months of Phe levels below 360 μmol/L)

Exclusion

  • History of major neurologic disorder unrelated to PKU
  • Contraindications for safe MRI participation such as (a) pregnancy or plans to become pregnant during period of study enrollment; or (b) metallic objects inside the body (e.g., surgical staples left in the body following surgery, middle ear prosthesis, metal foreign objects lodged inside the eye, heart pacemakers).
  • Current participation in an interventional clinical trial (not Palynziq-related).

Key Trial Info

Start Date :

May 25 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 1 2025

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT05356377

Start Date

May 25 2022

End Date

July 1 2025

Last Update

December 29 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Boston Children's Hospital

Boston, Massachusetts, United States, 02115

2

University of Missouri

Columbia, Missouri, United States, 65211

Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU | DecenTrialz